The GNRH1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line, with targeted disruption of the gonadotropin-releasing hormone 1 (GNRH1) gene. This loss-of-function model, generated via CRISPR/Cas9-mediated gene disruption, provides a genetically defined system to interrogate the roles of autocrine and paracrine GnRH signaling in a gastric epithelial context. The product is supplied as a heterogeneous polyclonal population, reflecting a pool of edited cells with diverse modifications at the GNRH1 locus, enabling robust and reproducible functional studies without clonal bias.
The AGS cell line, originally derived from a gastric adenocarcinoma of a 54-year-old female, exhibits an adherent epithelial morphology and is widely employed as a model for gastric cancer. These cells harbor genetic and phenotypic characteristics typical of gastric adenocarcinoma, making them a relevant host for dissecting molecular mechanisms underlying tumor progression. When applied to the GNRH1 knockout, the AGS background allows investigation of how loss of this neuropeptide hormone influences gastric cancer cell behavior, including proliferation, motility, and signal transduction, within a well-characterized disease-relevant environment.
GNRH1 encodes gonadotropin-releasing hormone, an autocrine/paracrine factor that activates its cognate receptor GNRHR, a G??q/11-coupled GPCR. Ligand binding stimulates PLC??, generating DAG and IP3, which activate PKC and mobilize calcium, leading to phosphorylation of ERK1/2 and AKT, while also engaging cAMP/PKA. These pathways regulate transcription factors CREB, c-Fos, and c-Jun, and drive expression of cyclin D1, MMP-2, MMP-9, and VEGF. Interacting partners ??-arrestin, calmodulin, and prohormone convertases fine-tune signaling. GNRH1 knockout disrupts this autocrine cascade, attenuating MAPK/ERK and PI3K/AKT activity. GNRH1 itself is regulated by KISS1, estradiol, leptin, SP1, and NF-??B, linking nutrient and hormonal cues.
In AGS gastric cancer cells, autocrine GnRH signaling promotes proliferation, migration, and invasion, contributing to malignancy. By eliminating GNRH1, this knockout model enables dissection of hormone-driven oncogenic signals and crosstalk between reproductive hormones and tumor pathways. It provides a system to study attenuated ERK1/2 and AKT signaling, reduced cyclin D1 and MMP expression, and altered cellular responses to GnRH analogs, all within a clinically relevant gastric adenocarcinoma background.
Applications span GnRH pathway investigation, validation of therapeutic GnRH analogs, and signaling studies in gastric cancer. Compatible assays include Western blotting for phospho-ERK1/2 and total CREB; RT-qPCR for downstream targets; MTT or BrdU proliferation assays; Transwell migration/invasion; calcium flux; and apoptosis detection by Annexin V. GnRH agonist/antagonist treatments can further probe receptor pharmacology. These polyclonal knockout cells are a robust tool for academic and pharmaceutical research. For technical inquiries and purchasing, contact Ascent Research.
